Ocular Hypertension Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The ocular hypertension market reached a value of USD 3,166.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4,752.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.77% during 2025-2035.

The ocular hypertension market has been comprehensively analyzed in IMARC's new report titled "Ocular Hypertension Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Ocular hypertension refers to a condition characterized by higher-than-normal intraocular pressure (IOP) in the eye. Intraocular pressure is the fluid pressure inside the eye, maintained by the balance between the production and drainage of fluid called aqueous humor. Most people suffering from ocular hypertension are asymptomatic, but some patients may occasionally experience mild eye discomfort, including a feeling of pressure or aching in the eye. In rare cases, ocular hypertension may be accompanied by mild headaches, particularly around the temples or in the forehead. The diagnosis of ocular hypertension is typically made during a comprehensive eye examination. The main diagnostic criterion is the measurement of intraocular pressure using instruments like a tonometer. In general, an IOP reading of 21 mmHg or higher is considered elevated and indicative of ocular hypertension. The eye care professional may also assess the optic nerve through various techniques, such as ophthalmoscopy and optical coherence tomography (OCT). Additionally, a thorough examination of the anterior chamber angle may be performed to assess the drainage structures of the eye.

To get more information on this market, Request Sample

The escalating cases of inflammation, scarring, or structural abnormalities in the eye resulting from trauma or surgery, which can impair the proper outflow of aqueous humor, are primarily driving the ocular hypertension market. In addition to this, the rising prevalence of several associated risk factors, including genetic predisposition, age-related changes in the eye's drainage system, underlying systemic conditions like diabetes, prolonged use of corticosteroids, etc., is also bolstering the market growth. Furthermore, the inflating adoption of topical eye drops to lower elevated intraocular pressure by increasing the outflow of aqueous humor or reducing its production is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cyclophotocoagulation, which uses laser or cryotherapy to target the ciliary body, thereby lowering its ability to produce aqueous humor, is also creating a positive outlook for the market. Apart from this, the escalating utilization of selective laser trabeculoplasty on account of its several associated benefits, such as targeted treatment without damaging surrounding tissues, minimal downtime and quick recovery, potential long-term advantages with sustained intraocular pressure control, etc., is expected to drive the ocular hypertension market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the ocular hypertension market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ocular hypertension and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ocular hypertension market in any manner.

Recent Developments:

• In June 2025, Nicox announced that the last patient had completed its Denali phase 3 trial, which is evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The company noted that all 696 patients in the trial had completed their treatment and follow-up visits.
• In September 2024, Santen Pharmaceutical announced that it had applied to manufacturing and marketing approval of STN1012600 for the treatment of glaucoma and ocular hypertension in Japan.
• In April 2024, Ocular Therapeutix announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension.

Drugs:

Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a mixture of two prescription drugs that relieve high eye pressure (IOP) in people with open-angle glaucoma or ocular hypertension. The drug is recommended to be administered at a dosage of one drop once daily in the evening in the affected eye(s). Rocklatan reduces IOP in ocular hypertension by increasing the outflow of aqueous humor through both conventional and unconventional pathways.

QLS-101 is a new ATP-sensitive potassium (KATP) channel modulator delivered as a topical eyedrop. It addresses distal outflow resistance and episcleral venous pressure (EVP), which are important components of IOP. It also reduces IOP by expanding outflow channels and episcleral arteries in the eye distal to the trabecular meshwork.

OTX TIC, a bioresorbable implant from Ocular Therapeutix, utilizes a hydrogel depot to release travoprost, a prostaglandin analog, into the anterior chamber of the eye for sustained IOP reduction in patients with glaucoma or ocular hypertension. The implant is designed to deliver the drug over several months, addressing the issue of poor patient compliance with topical eye drops.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ocular hypertension market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ocular hypertension market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ocular hypertension marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the ocular hypertension market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the ocular hypertension across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the ocular hypertension across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of ocular hypertension across the seven major markets?
• What is the number of prevalent cases (2019-2035) of ocular hypertension by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of ocular hypertension by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with ocular hypertension across the seven major markets?
• What is the size of the ocular hypertension patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend ocular hypertension of?
• What will be the growth rate of patients across the seven major markets?

Ocular Hypertension: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for ocular hypertension drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ocular hypertension market?
• What are the key regulatory events related to the ocular hypertension market?
• What is the structure of clinical trial landscape by status related to the ocular hypertension market?
• What is the structure of clinical trial landscape by phase related to the ocular hypertension market?
• What is the structure of clinical trial landscape by route of administration related to the ocular hypertension market?